Beta3-adrenergic Receptors and Cardiovascular Function in Aging Women

ConditionsWomen Aging Menopause

Trial statusNot yet recruiting

Trial phaseEarly Phase 1

Trial typeInterventional

Biological sexFemale

Age18-70

SponsorUniversity of Missouri-Columbia

About this trial

We hypothesize vascular beta3 adrenergic receptors are present and functional in aging women and can be targeted to attenuate sympathetic vasoconstriction and enhance vascular function in aging women.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

Placebo
Gemtesa

Treatment groups

60 Participants

are divided into 2 treatment groups

Sponsors and collaborators

University of Missouri-Columbia

Lead sponsor

Source ClinicalTrials.gov